Health Condition 1: C642- Malignant neoplasm of left kidney,except renal pelvis Health Condition 2: C641- Malignant neoplasm of right kidney, except renal pelvis Health Condition 3: C649- Malignant neoplasm of unspecifiedkidney, except renal pelvis Health Condition 4: C659- Malignant neoplasm of unspecifiedrenal pelvis
Conditions
Interventions
None listed
Sponsors
Innsbruck Medical University
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion Criteria for the patients: 1.Patients with a diagnosis of renal cell cancer (irrespective of treatment or follow up status) 2.Patients who are18 years of age or above 3.Patients with no other concurrent malignancies 4.Patients with no cognitive impairment 5.Patients willing to provide written informed consent for the study Inclusion criteria for HCPs: 1.Consultants from any of the specialist disciplines of medical oncology, surgical oncology, other (radiation oncology) treating patients with RCC 2.Consultants of either gender 3.Willing to participate and provide a written informed consent
Exclusion criteria
Exclusion criteria: Exclusion criteria for patients: 1.None. Anyone fulfilling the inclusion criteria will be eligible for the study. Exclusion criteria for HCPs: 1.None. Anyone fulfilling the inclusion criteria will be eligible for the study 2.Patients not willing to provide written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Is to develop a provisional questionnaire ready for pre-testing in Phase III as per the module development guidelines of the EORTC Quality of Life Group (QLG)Timepoint: baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| NoneTimepoint: Not applicable | — |
Countries
India, Norway, United Kingdom
Contacts
Public ContactDr Manjunath Nookala Krishnamurthy
Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre
Outcome results
None listed